Search

Displaying results 2011 - 2020 of 3733 in total
  1. Target

    Ribosome-binding protein 1

    go.drugbank.com/bio_entities/BE0003466
    TargetHumans

    Acts as a ribosome receptor and mediates interaction between the ribosome and the endoplasmic reticulum membrane

    Synonyms: Ribosome receptor protein, 180 kDa ribosome receptor homolog
  2. Target

    Natural killer cells antigen CD94

    go.drugbank.com/bio_entities/BE0010559
    TargetHumans

    Immune receptor involved in self-nonself discrimination.

    Synonyms: NK cell receptor, Killer cell lectin-like receptor subfamily D member 1Function: HLA-A specific activating MHC class I receptor activity
  3. Target

    V-type immunoglobulin domain-containing suppressor of T-cell activation

    go.drugbank.com/bio_entities/BE0010797
    TargetHumans

    Immunoregulatory receptor which inhibits the T-cell response (PubMed:24691993). May promote differentiation of embryonic stem cells, by inhibiting BMP4 signaling (By similarity).

    Synonyms: Platelet receptor Gi24, V-set immunoregulatory receptor
  4. Drug

    Multipotent adult arogenitor cells

    go.drugbank.com/drugs/DB15742
    Investigational

    After administration, the cells are cleared from the body over time. Currently, MultiStem is being investigated against neurological, inflammatory, immune, and cardiovascular diseases and conditions.

  5. Target

    Integrin beta-7

    go.drugbank.com/bio_entities/BE0003414
    TargetHumans

    Integrin ITGAE/ITGB7 (alpha-E/beta-7, HML-1) is a receptor for E-cadherin (PubMed:10837471) … Integrin ITGA4/ITGB7 (alpha-4/beta-7) (Peyer patches-specific homing receptor LPAM-1) is an adhesion molecule that mediates lymphocyte migration and homing to gut-associated lymphoid tissue (GALT) (Probable

    Synonyms: Gut homing receptor beta subunit
  6. Drug

    Protamine sulfate

    go.drugbank.com/drugs/DB09141
    ApprovedInvestigational

    formal introduction via US FDA approval in 1939, protamine sulfate has occupied an important therapeutic niche as perhaps the only viable option for reversing the anticoagulant effect of heparin use for over

  7. Drug

    CYP-001

    go.drugbank.com/drugs/DB15739
    Investigational

    These cells have advantage over other MSCs because a large amount can be obtained from a single healthy blood donor, negating the risks from donor-and expansion dependent variability.

  8. Drug

    IMM101

    go.drugbank.com/drugs/DB15851
    Experimental

    As of July 2020, researchers from the Ottawa Hospital and Queen’s University, in partnership with the Canadian Cancer Society-funded Canadian Cancer Trials Group (CCTG), are conducting a trial in over

  9. Drug

    ATX-101

    go.drugbank.com/drugs/DB05780
    Investigational

    ATX-101 demonstrates a relative selectivity for fat over other tissues.

  10. Drug

    Sodium phosphate, dibasic, unspecified form

    go.drugbank.com/drugs/DB14504
    Approved

    Mixtures: Isolyte S pH 7.4